Art Krieg leads Checkmate as it comes out of stealth mode with $20M

Alok Saboo FierceBiotech News

Symbiomix pops out of stealth mode with $41M and a looming PhIII

John Carroll In the little more than two years since its launch, Symbiomix Therapeutics has successfully navigated a midstage study for a sole-asset antibiotic, positioning it for a ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS